New renin-angiotensin-system (RAS) inhibitor therapy using sacubitril-valsartan (Entresto) is no more likely to cause angioedema than starting out with an ACE inhibitor or angiotensin receptor blocker ...

Patients with heart failure who start taking sacubitril/valsartan (Entresto; Novartis) do not appear to have a greater risk of angioedema than do those who opt for an ACE inhibitor or ARB instead, an ...